FDA-cleared profile

LARALAB

LARALAB GmbH · CT/CTA · FDA-cleared (510(k))

Authorized purpose: Cardiac CT segmentation, measurement and valve-intervention planning

Clinical role
Segmentation or contouring; measurement and planning support
Images and patients
CT/CTA · Heart/Cardiovascular
Key limitation
Keep in mind: Automated segmentations and measurements can be reviewed and adjusted manually. Clinical validation described patients aged 62 and older.

Overview status: Source-reviewed overview

Report a correction
Clinical details Purpose, workflow fit, evidence, and safety record

Workflow navigation pilot

Workflow role has not yet been reviewed for this navigation pilot.

A tag identifies a documented role; it does not establish compatibility or local acceptance. Methods and sources

  • What does this software do?Authorized purpose: Cardiac CT segmentation, measurement and valve-intervention planning
  • Which images or clinical context are in scope?Modality: CT/CTA Anatomy or clinical context: Heart/Cardiovascular Input: DICOM-compliant CT images of heart and vessels for aortic, mitral and tricuspid valve intervention planning
  • Who uses it?Intended users: Cardiologists, radiologists, heart surgeons and healthcare professionals
  • What does the software produce?Output: Cardiovascular and calcification segmentations; splines, distances, angulation and volume measurements; MPR and surface-rendered views; assessments and PDF planning reports
  • What is its most important limitation?Key limitation: Automated segmentations and measurements can be reviewed and adjusted manually. Clinical validation described patients aged 62 and older.

Clinical takeaway. Clinical role: Cardiac CT segmentation, measurement and valve-intervention planning

Evidence takeaway. Evidence from the reviewed source record: Multicenter standalone observational evaluation of 60 CT cases, divided equally across aortic, mitral and tricuspid planning; expert manual measurements using 3mensio served as comparator. Patients were aged 62-97; 45% were male.

Evidence context

Evidence context not reviewed for this FDA record.

Public-label constraints

Label constraints have not been reviewed for this exact FDA record. Unknown is not all ages or evidence of unsuitability.

Public-label constraints, not patient-level eligibility or a medical recommendation. Training and evaluation populations are separate. Read the original labeling and confirm the exact release and protocol.

Purpose
Cardiac CT segmentation, measurement and valve-intervention planning
  • Exact FDA submission
  • Checked 2026-09-05
Workflow role
Segmentation or contouring; measurement and planning support
  • Exact FDA submission
  • Checked 2026-09-05
Required input
DICOM-compliant CT images of heart and vessels for aortic, mitral and tricuspid valve intervention planning
  • Exact FDA submission
  • Checked 2026-09-05
Output and clinician action
Cardiovascular and calcification segmentations; splines, distances, angulation and volume measurements; MPR and surface-rendered views; assessments and PDF planning reports
  • Exact FDA submission
  • Checked 2026-09-05
Care setting
Adult cardiovascular intervention and surgery planning
  • Exact FDA submission
  • Checked 2026-09-05

Validation patients were 62-97 years old; this is not evidence for all adult subgroups.

Intended users
Cardiologists, radiologists, heart surgeons and healthcare professionals
  • Exact FDA submission
  • Checked 2026-09-05
Limitations
Automated segmentations and measurements can be reviewed and adjusted manually. Clinical validation described patients aged 62 and older.
  • Exact FDA submission
  • Checked 2026-09-05
Evidence summary
Multicenter standalone observational evaluation of 60 CT cases, divided equally across aortic, mitral and tricuspid planning; expert manual measurements using 3mensio served as comparator. Patients were aged 62-97; 45% were male.
  • Exact FDA submission
  • Checked 2026-09-05

Evidence

Performance evidence

Metrics are shown only when they are tied to a source, endpoint, population, and tested product version. Candidate literature without exact product and version linkage is not shown as product evidence.

Evidence summary
Multicenter standalone observational evaluation of 60 CT cases, divided equally across aortic, mitral and tricuspid planning; expert manual measurements using 3mensio served as comparator. Patients were aged 62-97; 45% were male.
  • FDA source
  • Exact FDA submission
  • Checked 2026-09-05
Reported sensitivity
Not established in reviewed sources
  • Reviewed sources checked
  • Exact FDA submission
  • Checked 2026-09-05

Reviewed measurement-comparison evidence does not establish a general diagnostic sensitivity.

Reported specificity
Not established in reviewed sources
  • Reviewed sources checked
  • Exact FDA submission
  • Checked 2026-09-05

A diagnostic specificity was not established in the reviewed planning study.

No contextualized exact-version metric has completed evidence review. Regulatory-document values, when available, are shown above with their limitations.

K242500 cardiac CT planning performance study

  • DesignMulticenter observational standalone comparison against expert 3mensio measurements
  • Population20 aortic, 20 mitral and 20 tricuspid CT cases; age 62-97
  • Scopeexact submission
  • Tested versionLARALAB evaluated in K242500
  • Samplen=60
  • IndependenceIndependence not established

K242500

Staged transcatheter mitral and tricuspid valve replacement case report

  • DesignClinical case report with LARALAB planning-tool image
  • PopulationOne 79-year-old man undergoing staged Tendyne mitral and MonarQ tricuspid procedures
  • Scopeproduct family
  • Tested versionLARALAB online planning tool; version unspecified
  • Samplen=1
  • IndependenceIndependence not established

PMID:40155128 · doi:10.1016/j.jaccas.2025.103534

Figure identifies LARALAB use; not a software-accuracy study or causal evidence of benefit.

Safety and lifecycle

Postmarket record

Recall and adverse-event records are shown only after product matching. Adverse-event reports do not establish incidence or causality.

Postmarket safety review
Not established in reviewed sources
  • Reviewed sources checked
  • Exact FDA submission
  • Checked 2026-09-04

No native submission-identifier match was found in the checked openFDA radiology recall snapshot. Product-name, manufacturer, and adverse-event searches remain necessary; this does not establish that no recall or safety report exists.

Pricing & contracts Public price, contract terms, and reimbursement

Price not public here; enter your quote

Not verified: Pricing information is recorded but not verified against a resolving source.

Reimbursement

IT implementation Deployment, interfaces, data handling, and support

System and version relationships

Match the AI release, system build, configuration and region. Source documentation does not establish acceptance of an installed system.

No specific system/version pairing has completed review for this FDA record. A broad DICOM or product-family statement does not establish a named viewer build's support.

Review Merge, Visage, Sectra, AGFA and IntelePACS context

Integration chain: evidence at each hop

Public source context, not tested interoperability. Each hop needs its own release/configuration evidence. Missing or unavailable routes are not documented incompatibility. All local tests are planned, not passed; no installed-system acceptance is recorded.

Acquisition/source → routing → AI processing → returned objects → viewer/worklist/report → support owner

No specific route context has been source-reviewed for this record. Obtain both endpoint builds and documents; this is not a finding of incompatibility.

  1. Acquisition/source

    Source context, not route validation: DICOM-compliant CT images of heart and vessels for aortic, mitral and tricuspid valve intervention planning

    Scope: Exact FDA submission.

    Confirm scanner/model, protocol, series completeness and both software builds.

    Field checked 2026-09-05 · LARALAB: K242500 decision and 510(k) summary

  2. Routing

    Source context, not route validation: Users upload deidentified local DICOM files and export PDF reports

    Scope: Exact FDA submission. Native PACS import in the predicate comparison must not be attributed to the subject device.

    Name gateways, destinations, transfer rules and failure visibility; a DICOM statement does not prove a route.

    Field checked 2026-09-05 · LARALAB: K242500 decision and 510(k) summary

  3. AI processing

    Source context, not route validation: The exact FDA package describes LARALAB as cloud-based, with cloud-based access as a new feature versus its predicate, requiring patient data to be uploaded rather than imported directly from a PACS. Current hosting, data flow, and commercial configuration require vendor confirmation.

    Scope: Exact FDA submission. Packet wording: "While LARALAB introduces new features, such as cloud-based access and automatic preprocessing through deep learning algorithms" … "The limited difference is due to the cloud-based nature of the subject device, which requires that patient data be uploaded, as opposed to directly importing data from a PACS system, into the local predicate device.". Read from the exact FDA decision document on 2026-11-14; this is the release-level description, not current commercial configuration.

    Confirm processing location, queue ownership, exclusions and exact AI build.

    Field checked 2026-11-14 · LARALAB: K242500 decision and 510(k) summary

  4. Returned objects

    Source context, not route validation: Cardiovascular and calcification segmentations; splines, distances, angulation and volume measurements; MPR and surface-rendered views; assessments and PDF planning reports

    Scope: Exact FDA submission.

    Confirm object classes, units, references and whether findings, overlays or measurements reach their intended destination.

    Field checked 2026-09-05 · LARALAB: K242500 decision and 510(k) summary

  5. Viewer/worklist/report

    Unresolved route: Cardiovascular and calcification segmentations; splines, distances, angulation and volume measurements; MPR and surface-rendered views; assessments and PDF planning reports

    Scope: Exact FDA submission.

    Confirm the named viewer/worklist/report build, display behavior and report transfer. Output support alone does not establish this endpoint. The displayed source describes output, not validated end-to-end delivery.

    Field checked 2026-09-05 · LARALAB: K242500 decision and 510(k) summary

  6. Support owner

    Unresolved route: Not established for the exact route.

    Scope: Scope not established.

    Name the local, platform and AI supplier support owners and escalation path.

Planned local route tests

No tests below have been performed or accepted.

  1. Patient/study identity (planned). Use approved non-patient test data to verify identifiers, accession and result-to-study linkage at every hop.
  2. Study completeness (planned). Test missing views/series, partial transfer, late arrivals, priors and unsupported acquisition inputs; confirm explicit refusal or fallback.
  3. Ordering and duplicates (planned). Send out-of-order, repeated and corrected studies; verify worklist order, deduplication and no misleading stale results.
  4. Report transfer (planned). Verify output object types, annotations, units, report content, destination and availability of original images.
  5. Access (planned). Verify authorized roles, audit trail, denied access and support ownership at each destination.
  6. Latency and failures (planned). Agree a workload and turnaround target; test queues, timeouts, missing results and fallback reading.
  7. Updates and rollback (planned). Define version change control, revalidation triggers, stop-use criteria and a tested rollback route.

Local implementation checklist

Agree the evidence and acceptance owner with your team and suppliers. Checkmarks apply to this page only and are not acceptance receipts.

Open the printable evaluation checklist

Deployment
The exact FDA package describes LARALAB as cloud-based, with cloud-based access as a new feature versus its predicate, requiring patient data to be uploaded rather than imported directly from a PACS. Current hosting, data flow, and commercial configuration require vendor confirmation.
  • Exact FDA submission
  • Checked 2026-11-14

Packet wording: "While LARALAB introduces new features, such as cloud-based access and automatic preprocessing through deep learning algorithms" … "The limited difference is due to the cloud-based nature of the subject device, which requires that patient data be uploaded, as opposed to directly importing data from a PACS system, into the local predicate device.". Read from the exact FDA decision document on 2026-11-14; this is the release-level description, not current commercial configuration.

Integration
Users upload deidentified local DICOM files and export PDF reports
  • Exact FDA submission
  • Checked 2026-09-05

Native PACS import in the predicate comparison must not be attributed to the subject device.

Current family viewer

Vendor describes a cloud-based heart.ai workflow with a 4D DICOM viewer

product family · checked 2026-09-05

Some advertised features are marked research use only; the current feature set is not equated with K242500.

Manual correction

Manual measurement and adjustment of automated planning results

exact submission · checked 2026-09-05
Sources & review details FDA identity, research record, source ledger, and history

Regulatory identity

FDA record and catalog context

The FDA listing establishes the regulatory identity. It does not by itself establish local workflow fit, pricing, security, or performance in your environment.

FDA submission
K242500
  • FDA source
  • Exact FDA submission
  • Checked 2026-08-31
Modality
CT/CTA
  • FDA source
  • Exact FDA submission
  • Checked 2026-09-05
Anatomy
Heart/Cardiovascular
  • FDA source
  • Exact FDA submission
  • Checked 2026-09-05
Clearance type
510(k)
  • FDA source
  • Exact FDA submission
  • Checked 2026-08-31
Decision date
2025-04-16
  • FDA source
  • Exact FDA submission
  • Checked 2026-08-31
FDA status
FDA-cleared
  • FDA source
  • Exact FDA submission
  • Checked 2026-08-31

Research record

What has been checked

This audit distinguishes completed source review from fields that have not yet been researched.

Human reviewedStatus
2026-09-05Last searched
21Fields reviewed
11Source classes checked
1Screened PubMed leads
1Screened trial leads
0Unreviewed FDA recall leads

PMID40155128 identifies the family planning tool in a single case and is retained contextually. NCT06951126 stored metadata concerns CT prediction for transcatheter tricuspid interventions; exact product/version applicability remains unestablished. Registry page returned a JavaScript shell; no trial outcomes promoted. The current discovery snapshot contains 1 PubMed and 1 ClinicalTrials.gov candidate records; its dated, count-matched human screening remains current. Unlinked candidates remain quarantined. Native FDA recall identifiers produced 0 postmarket candidate records; 0 have been reviewed (0 published, 0 rejected) and 0 remain unreviewed.

Candidate leads were screened against the exact product and tested version. Unlinked records remain quarantined.

Source classes: fda ai list, fda decision summary, acr ai central product, vendor product page, literature index, peer reviewed publication, trial registry, recall database, pubmed, clinical trials, openfda device recall

Field review details

Recorded state, verification date, notes and sources for fields without a publishable value. Conflicting records stay explicitly unsettled here; no plain settled value is shown for them.

  • Public pricing: Not verified - checked 2026-09-05 - Exact FDA submission

    Reviewed vendor pages did not establish a dated exact-version license or planning-case rate.

  • Pricing model: Not yet reviewed
  • Setup and integration fees: Not yet reviewed
  • Recurring fees: Not yet reviewed
  • Minimum commitment: Not yet reviewed
  • Contract duration: Not yet reviewed
  • Renewal terms: Not yet reviewed
  • Cancellation terms: Not yet reviewed
  • Support and service terms: Not yet reviewed
  • Trial or pilot terms: Not yet reviewed
  • Reimbursement: Not publicly available - checked 2026-10-26 - Exact FDA submission

    Bounded web search on 2026-10-26 (query: "Laralab reimbursement CPT"; top results reviewed) found no vendor or payer page stating coding, coverage or payment for this product. No result was a vendor or payer page naming this product with coding or payment; any results were general billing guidance. This records what was found, not that none exists.

  • Data hosting location: Not yet reviewed
  • Data retention: Not yet reviewed
  • Documented data use: Not yet reviewed
  • Hardware requirements: Not yet reviewed
  • Network requirements: Not yet reviewed
  • Identity and access: Not yet reviewed
  • Security: Not verified - checked 2026-09-05 - Exact FDA submission

    FDA-described access/encryption controls are not a current scoped security certification. Hosting region, retention, contractual data controls and dated attestations were not established.

  • Installation timeline: Not yet reviewed
  • Training: Not verified - checked 2026-09-05 - Exact FDA submission

    User qualification requirements beyond intended-user categories and the contracted onboarding package remain to be confirmed.

  • Monitoring: Not verified - checked 2026-09-05 - Exact FDA submission

    Site acceptance should address segmentation corrections and report transfer; this is editorial guidance, not a verified monitoring capability.

9 sources - 3 history items

Source ledger

  1. K242500 FDA decision source

    U.S. Food and Drug Administration - Accessed 2026-08-31

    Scope: regulatoryIdentity, purpose, modality, anatomy

  2. Artificial Intelligence-Enabled Medical Devices

    U.S. Food and Drug Administration - Accessed 2026-08-31

    Scope: regulatoryIdentity, modalityContext

  3. LARALAB GmbH model card (K242500)

    American College of Radiology - Published 2026-08-17 - Accessed 2026-09-01

    Scope: intendedUsers, careSetting, output, evidenceSummary, integration, anatomy, evidenceStudies, implementationCapabilities

  4. PubMed biomedical literature index

    U.S. National Library of Medicine - Accessed 2026-09-01

    Scope: evidenceDiscovery

  5. ClinicalTrials.gov study registry

    U.S. National Library of Medicine - Accessed 2026-09-01

    Scope: evidenceDiscovery, studyStatus

  6. openFDA Device Recall API

    U.S. Food and Drug Administration - Accessed 2026-09-02

    Scope: recallDiscovery, nativeSubmissionMatching

  7. LARALAB: K242500 decision and 510(k) summary

    U.S. Food and Drug Administration - Accessed 2026-09-05

    Scope: identity, clinical, evidence, implementation, deployment

  8. LARALAB heart.ai

    LARALAB - Accessed 2026-09-05

    Scope: implementation

  9. Staged transcatheter mitral and tricuspid valve replacement case report

    JACC Case Reports / PubMed - Published 2025-03-19 - Accessed 2026-09-05

    Scope: evidenceStudies

Research history

  1. K242500 FDA decision

    Regulatory record

    510(k)

  2. Source-review record updated

    Research record

    human reviewed

  3. Reader overview source-reviewed

    Editorial review

    Source-reviewed editorial overlay

Alternatives

Related tools to compare

FDA-cleared K252217

CT VScore+

Canon Medical Informatics, Inc.

Authorized purpose: CT VScore+ evaluates calcified coronary lesions on ECG-gated, non-contrast cardiac CT in patients aged 30 years or older, automatically generating coronary calcium scores and highlighted calcium segmentation for qualified clinical review.

Modality
CT/CTA
Anatomy
Heart/Cardiovascular
Decision
2025-11-28
FDA-cleared K251027

cvi42 Coronary Plaque Software Application

Circle Cardiovascular Imaging, Inc.

Authorized purpose: cvi42 Coronary Plaque supports qualified professionals with viewing, post-processing, and qualitative and quantitative evaluation of adult cardiac CT DICOM images to assess the presence and extent of coronary plaques and stenoses in CCTA for CAD or suspected CAD.

Modality
CT/CTA
Anatomy
Heart/Cardiovascular
Decision
2025-10-27
FDA-cleared K251656

Careverse CoronaryDoc (Careverse CoronaryDoc)

Careverse Technology Pte. Ltd.

Authorized purpose: Careverse CoronaryDoc is a web-based tool for trained medical professionals to view and analyze CCTA CT data for coronary plaques and stenosis, with coronary measurements, visualization, automated plaque and stenosis outputs, and structured reporting for physician review.

Modality
CT/CTA
Anatomy
Heart/Cardiovascular
Decision
2025-09-04

Correct this exact record

Copy this public context and add the field, proposed wording and original source before sending. Nothing here is submitted automatically. Form-specific prefill has not been verified.

Open existing correction destination

Permission to display a submission is not evidence verification. A submission enters editorial review; it does not approve a public change. Form availability, data entry, receipt, review and publication are separate steps. Data entry and receipt remain unverified.

Accepted repository change history

No entry has been added to this scoped change history for this record. This is not proof that the record never changed.

Correction policy and limits · Public repository change history